Adnexus Therapeutics, Inc. Company Profile

10:56 EST 18th November 2017 | BioPortfolio

Adnexus Therapeutics, Inc. (formerly Compound Therapeutics, Inc.) is focused on generating vital medicines through the discovery, development, and commercialization of our broadly applicable new therapeutic class, AdNectins™.
AdNectins have the potential to become a dominant class of protein therapeutics, overcoming the limitations of current protein classes, including antibodies and soluble receptors. AdNectins are designed and optimized using PROfusion™, Adnexus' proprietary protein design technology that uniquely enables selection of molecules with ideal product characteristics. Together, AdNectins and PROfusion are a powerful combination that enables the design and production of product candidates with desired drug properties for a wide variety of targets and therapeutic areas.

Adnexus is developing a portfolio of AdNectin therapeutic products. Angiocept™ (CT-322), an AdNectin that inhibits the activation of human vascular endothelial growth factor receptor 2 (VEGFR-2), is Adnexus' first product that was designed using this proprietary approach. Angiocept (CT-322) is scheduled to begin Phase I clinical studies in oncology in 2006.

Adnexus Therapeutics is led by a management team and Board of Directors with extensive industry experience covering all aspects of building successful biopharmaceutical companies. Collectively, the team has developed and launched over 20 marketed biologic products. The Company is backed by four leading venture firms: Atlas Venture, Flagship Ventures, Polaris Venture Partners, and Venrock Associates.


100 Beaver Street
United States of America


Phone: (781) 891-3745
Fax: (781) 891-3796

News Articles [507 Associated News Articles listed on BioPortfolio]

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

Bristol-Myers Squibb: Business Development in a Global Community

In this exclusive interview, Fintan Walton talks to Graham Brazier, Vice President and Head of Business Development at Bristol-Myers Squibb (BMS), about the world of big pharma business development an...

Ms. Teresa Regan Joins Neon Therapeutics as VP of Human Resources

Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, today announced that Teresa (Terry) Reg...

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...

Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, ... Cytori Therapeutics San Diego, Californiaheadquartered Cytori Therapeutics Inc.'s shares dropped 2.15%, closing Monday's trading session at $0.39. The stock ...

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...

SMi Group announces the 9th Annual RNA Therapeutics Conference

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towar...

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1168 Associated Companies listed on BioPortfolio]

Adnexus Therapeutics, Inc

Adnexus Therapeutics, Inc. (formerly Compound Therapeutics, Inc.) is focused on generating vital medicines through the discovery, development, and commercialization of our broadly applicable new thera...

Adnexus Therapeutics, Inc.

Adnexus Therapeutics, Inc. (formerly Compound Therapeutics, Inc.) is focused on generating vital medicines through the discovery, development, and commercialization of our broadly applicable new thera...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Adnexus Therapeutics, Inc." on BioPortfolio

We have published hundreds of Adnexus Therapeutics, Inc. news stories on BioPortfolio along with dozens of Adnexus Therapeutics, Inc. Clinical Trials and PubMed Articles about Adnexus Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Adnexus Therapeutics, Inc. Companies in our database. You can also find out about relevant Adnexus Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Corporate Database Quicklinks

Searches Linking to this Company Record